159 related articles for article (PubMed ID: 35238098)
21. Tumor-infiltrating gamma delta T-cells reveal exhausted subsets with remarkable heterogeneity in colorectal cancer.
Yu L; Wang Z; Hu Y; Wang Y; Lu N; Zhang C
Int J Cancer; 2023 Nov; 153(9):1684-1697. PubMed ID: 37531161
[TBL] [Abstract][Full Text] [Related]
22. CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.
Flores-Toro JA; Luo D; Gopinath A; Sarkisian MR; Campbell JJ; Charo IF; Singh R; Schall TJ; Datta M; Jain RK; Mitchell DA; Harrison JK
Proc Natl Acad Sci U S A; 2020 Jan; 117(2):1129-1138. PubMed ID: 31879345
[TBL] [Abstract][Full Text] [Related]
23. Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells.
Odorizzi PM; Pauken KE; Paley MA; Sharpe A; Wherry EJ
J Exp Med; 2015 Jun; 212(7):1125-37. PubMed ID: 26034050
[TBL] [Abstract][Full Text] [Related]
24. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
25. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer.
Xu B; Yuan L; Gao Q; Yuan P; Zhao P; Yuan H; Fan H; Li T; Qin P; Han L; Fang W; Suo Z
Oncotarget; 2015 Aug; 6(24):20592-603. PubMed ID: 26008981
[TBL] [Abstract][Full Text] [Related]
26. IL8 derived from macrophages inhibits CD8
Zhao C; Wang D; Li Z; Zhang Z; Xu Y; Liu J; Lei Q; Han D; Huo Y; Liu S; Li L; Zhang Y
Int Immunopharmacol; 2023 Aug; 121():110457. PubMed ID: 37331296
[TBL] [Abstract][Full Text] [Related]
27. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
28. Gegen Qinlian decoction enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by remodelling the gut microbiota and the tumour microenvironment.
Lv J; Jia Y; Li J; Kuai W; Li Y; Guo F; Xu X; Zhao Z; Lv J; Li Z
Cell Death Dis; 2019 May; 10(6):415. PubMed ID: 31138779
[TBL] [Abstract][Full Text] [Related]
29. Stem-like progenitor and terminally differentiated T
Zhou W; Kawashima S; Ishino T; Kawase K; Ueda Y; Yamashita K; Watanabe T; Kawazu M; Dansako H; Suzuki Y; Nishikawa H; Inozume T; Nagasaki J; Togashi Y
Cell Rep; 2024 Feb; 43(2):113797. PubMed ID: 38363680
[TBL] [Abstract][Full Text] [Related]
30. TIM3 comes of age as an inhibitory receptor.
Wolf Y; Anderson AC; Kuchroo VK
Nat Rev Immunol; 2020 Mar; 20(3):173-185. PubMed ID: 31676858
[TBL] [Abstract][Full Text] [Related]
31. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
[No Abstract] [Full Text] [Related]
32. The Network Pharmacology Study of Dahuang Fuzi Decoction for Treating Incomplete Intestinal Obstruction.
Guo JF; Zhao YT; Du QY; Ren Y; Wang Y; Wang ZX; Jin W
Biomed Res Int; 2022; 2022():2775434. PubMed ID: 35528155
[TBL] [Abstract][Full Text] [Related]
33. Probiotics Can Boost the Antitumor Immunity of CD8
Mao J; Zhang SZ; Du P; Cheng ZB; Hu H; Wang SY
J Immunol Res; 2020; 2020():4092472. PubMed ID: 32455139
[TBL] [Abstract][Full Text] [Related]
34. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
Ngiow SF; von Scheidt B; Akiba H; Yagita H; Teng MW; Smyth MJ
Cancer Res; 2011 May; 71(10):3540-51. PubMed ID: 21430066
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells.
Bannoud N; Dalotto-Moreno T; Kindgard L; García PA; Blidner AG; Mariño KV; Rabinovich GA; Croci DO
Front Immunol; 2021; 12():660944. PubMed ID: 34025660
[TBL] [Abstract][Full Text] [Related]
36. Type 17 immunity promotes the exhaustion of CD8
Kim BS; Kuen DS; Koh CH; Kim HD; Chang SH; Kim S; Jeon YK; Park YJ; Choi G; Kim J; Kang KW; Kim HY; Kang SJ; Hwang S; Shin EC; Kang CY; Dong C; Chung Y
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083422
[TBL] [Abstract][Full Text] [Related]
37. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Sakuishi K; Apetoh L; Sullivan JM; Blazar BR; Kuchroo VK; Anderson AC
J Exp Med; 2010 Sep; 207(10):2187-94. PubMed ID: 20819927
[TBL] [Abstract][Full Text] [Related]
38. Rgs16 promotes antitumor CD8
Weisshaar N; Wu J; Ming Y; Madi A; Hotz-Wagenblatt A; Ma S; Mieg A; Hering M; Zettl F; Mohr K; Schlimbach T; Ten Bosch N; Hertel F; Müller L; Byren H; Wang M; Borgers H; Munz M; Schmitt L; van der Hoeven F; Kloz U; Carretero R; Schleußner N; Jackstadt RF; Hofmann I; Cui G
Sci Immunol; 2022 May; 7(71):eabh1873. PubMed ID: 35622904
[TBL] [Abstract][Full Text] [Related]
39. Skin dendritic cells in melanoma are key for successful checkpoint blockade therapy.
Prokopi A; Tripp CH; Tummers B; Hornsteiner F; Spoeck S; Crawford JC; Clements DR; Efremova M; Hutter K; Bellmann L; Cappellano G; Cadilha BL; Kobold S; Boon L; Ortner D; Trajanoski Z; Chen S; de Gruijl TD; Idoyaga J; Green DR; Stoitzner P
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408092
[TBL] [Abstract][Full Text] [Related]
40. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
